PRESS RELEASE

EXCiPACT CELEBRATES ITS 100TH CERTIFICATION OF PHARMACEUTICAL EXCIPIENT SUPPLIERS

Brussels, 17 December 2019

EXCiPACT asbl is celebrating the award of the 100th GMP and/or GDP Certificate by one of its internationally recognised Certification Bodies to either a manufacturer and/or a distributor of pharmaceutical excipients!

We are most grateful for the support of the regulators and of our seven partner Certification Bodies – AENOR, AJA, Blue, Bureau Veritas, Certiquality, DQS and SGS - who have worked hard to help us achieve this result sooner than expected. Their continued support will be needed to help us reach our next target of 150 certificates!

Third-party certification in the pharma sector was in its infancy in 2014 when we became an independent, non-profit organisation. We are proud of the positive contribution made by the EXCiPACT Certification Scheme to (1) the reduction of the audit burden for both suppliers and users of pharma excipients and (2) to the security of the pharma supply chain for the benefit of patients globally.

Full details of all 100 certifications across seventeen countries can be seen at https://www.excipact.org/certificate-holders.html.

The President of EXCiPACT, Dr Iain Moore of Croda, says “I am honoured to be part of a passionate team of experts who designed, built and delivered EXCiPACT for the benefit of all stakeholders, including most critically, the patients. This huge milestone for EXCiPACT means our team can rightly be proud of their contributions. With their dedication I am sure more success will follow.”

Notes for the Editor

EXCiPACT asbl provides management oversight for the voluntary, independent, high quality, international EXCiPACT Certification Scheme that provides for independent third-party GMP and/or GDP certification of manufacturers, suppliers and distributors of pharmaceutical excipients worldwide. The Scheme ensures patient safety through supplier quality while minimising the overall costs for assessing the excipient supply chain. It has been operational since early 2013 since when there has been considerable interest among pharmaceutical excipient suppliers, their customers and regulators. For further information see www.excipact.org or contact info@excipact.org